H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Repligen (RGEN – Research Report) today and set a price target of $180.00.
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Repligen’s strong performance and strategic initiatives. The company reported a modest top-line beat in its 1Q25 financial results, with revenue slightly exceeding expectations. Repligen has also revised its full-year 2025 revenue guidance upwards, indicating confidence in its growth prospects. The acquisition of 908 Devices’ bioprocessing portfolio and the launch of the CTech SoloVPE Plus System further strengthen its product offerings and market position.
Additionally, Repligen’s exposure to tariffs appears to be limited, with most of its manufacturing based in the U.S. and a significant portion of its revenue exempt from tariffs. The company’s proactive measures to mitigate potential tariff impacts, such as leveraging its global manufacturing network, suggest a well-managed approach to external challenges. These factors, combined with strong order trends and strategic expansions, underpin Selvaraju’s Buy rating and the 12-month price target of $180 per share.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 11.3% and a 43.03% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Vanda, and Anavex Life Sciences.
In another report released on April 30, Leerink Partners also maintained a Buy rating on the stock with a $200.00 price target.